- Home
- DAWN vs PGNY Comparison
DAWN vs PGNY Comparison
Compare DAWN & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAWN | PGNY |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DAWN | PGNY |
|---|---|---|
| Price | $21.52 | $25.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $24.43 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 2.7M | 1.7M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.04 |
| EPS | N/A | ★ 0.29 |
| Revenue | $158,182,000.00 | ★ $1,288,661,000.00 |
| Revenue This Year | $55.03 | $8.87 |
| Revenue Next Year | $28.12 | $9.76 |
| P/E Ratio | ★ N/A | $86.17 |
| Revenue Growth | ★ 20.60 | 10.40 |
| 52 Week Low | $5.64 | $16.10 |
| 52 Week High | $21.53 | $28.75 |
Technical Indicators
Market Signals| Indicator | DAWN | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 80.29 | 67.70 |
| Support Level | $10.30 | $25.14 |
| Resistance Level | N/A | $27.51 |
| Average True Range (ATR) | 0.03 | 0.93 |
| MACD | -0.28 | -0.08 |
| Stochastic Oscillator | 90.91 | 85.75 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.